|
ORLANDO, FL, Feb 05, 2008 (MARKET WIRE via COMTEX) -- Cardiovascular Sciences,
Inc. (PINKSHEETS: CVSC) announced
today that following the recent funding event, the Company has been able to reach
an agreement with the University of Central Florida to continue the Company's
research and development on its post-surgical anti-adhesion technology. Adhesions
occur after surgery when two normally separate but adjacent tissues that have
been injured or stressed scar together. Adhesions are part of the normal healing
process, but when they occur between tissues that are not normally attached,
problems ranging from mild discomfort to life threatening intestinal obstruction
can occur. The global market to address the problem of adhesions and adhesion
related complications exceeds $6 billion.
To this point, the collaboration between Cardiovascular Sciences,
Inc. and UCF has produced a second-generation material
with physical properties which appear to have exceeded
the initially designed criteria. At surgery, this material
is placed over and between areas likely to produce adhesions
and are gradually degraded and resorbed by the body after
the period in which adhesions are likely to occur, has
passed. This next phase in the Company's development will
involve several areas of investigation. One will be to
devise methods to manipulate the physical characteristics
of the material in order to broaden the range of indications
in which the material will be useful. A second will be to expand
the animal trials beyond the proof-of-concept phase so
that data can be gathered to support the requirements to
bring this product to market, first in the veterinary arena
and on to use in human clinical medicine.
Physician and company CEO, Larry Hooper, exclaims, "The
further we have come in this development, the increased number
of potential uses and indications we have encountered. We have
received several inquiries from fields we never expected, expressing
to us additional proposed uses for our technology in areas we
did not have in mind when we started."
Cardiovascular Sciences, Inc. has offices located in the Research
Park adjacent to the UCF campus and is a client company of the
award winning UCF High Tech Incubator program. Gordon Hogan,
the Incubator's Business Development Executive, is quick to
praise, "It is exciting to watch Cardiovascular Sciences
leverage their existing management strengths with the scientific
and technological strengths of UCF. This convergence can easily
result in dramatic changes in the prevention of surgical adhesions."
About Cardiovascular Sciences, Inc.
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions. Adhesions
and the complications of adhesions are a significant problem
worldwide for a wide range of specialists, including general
surgeons, cardiothoracic surgeons, orthopedic, plastic, ophthalmologic
and otolaryngology specialists to name just some of them. In
addition, the veterinary field has a tremendous need for a product
that can prevent similar problems in a wide variety of animals.
The Company's unique materials and processes promise a more
cost-effective and decidedly more efficient and capable means
to deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida
(UCF) and previously
at other institutions indicate that The Company is on the right
path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters,
cell engineered vascular tissues, and a method for improved
recovery of the heart following cardioplegia. This yields a
diversified portfolio with projects in various stages of development.
Forward-looking statements in this release are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject
to certain risks, and uncertainties and actual results could
differ from those discussed. This material is information only
and is not an offer or solicitation to buy or sell the securities.
For more information contact:
Cardiovascular Sciences Investor Relations
800-858-7502
ir@cvsciences.org
SOURCE: Cardiovascular Sciences
mailto:ir@cvsciences.org
Copyright 2008 Market Wire, All rights reserved.
http://www.foxbusiness.com/markets/industries/health-care/article/cardiovascular-sciences-agrees-terms-university-central-florida_465323_10.html |
